Cardinal Health (NYSE:CAH) Price Target Raised to $274.00 at Robert W. Baird

Cardinal Health (NYSE:CAH) had its target price increased by investment analysts at Robert W. Baird from $251.00 to $274.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Robert W. Baird’s price objective would suggest a potential upside of 14.13% from the company’s previous close.

A number of other analysts have also weighed in on the stock. Bank of America raised their price target on shares of Cardinal Health from $240.00 to $260.00 and gave the company a “buy” rating in a report on Thursday, July 2nd. Wall Street Zen raised Cardinal Health from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 4th. William Blair began coverage on Cardinal Health in a research report on Tuesday, April 28th. They issued an “outperform” rating on the stock. Weiss Ratings upgraded Cardinal Health from a “buy (b)” rating to a “buy (b+)” rating in a research report on Wednesday, August 5th. Finally, Zacks Research lowered Cardinal Health from a “strong-buy” rating to a “hold” rating in a research note on Friday, June 12th. Fifteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $254.60.

Cardinal Health Stock Performance

Shares of NYSE CAH opened at $240.08 on Wednesday. The business has a fifty day moving average of $228.37 and a two-hundred day moving average of $216.66. Cardinal Health has a 52-week low of $137.75 and a 52-week high of $258.30. The stock has a market cap of $56.23 billion, a PE ratio of 36.71, a PEG ratio of 1.16 and a beta of 0.49.

Cardinal Health (NYSE:CAH) last released its quarterly earnings results on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $2.42 by $0.49. Cardinal Health had a negative return on equity of 92.61% and a net margin of 0.62%.The business had revenue of $63.67 billion for the quarter, compared to analyst estimates of $65.15 billion. During the same period in the prior year, the company earned $2.08 EPS. Cardinal Health’s revenue for the quarter was up 5.8% on a year-over-year basis. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. Analysts predict that Cardinal Health will post 10.77 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CAH. LWM Advisors Inc. lifted its position in shares of Cardinal Health by 4.4% during the 2nd quarter. LWM Advisors Inc. now owns 1,028 shares of the company’s stock valued at $244,000 after acquiring an additional 43 shares during the period. Kathmere Capital Management LLC lifted its position in shares of Cardinal Health by 1.2% in the first quarter. Kathmere Capital Management LLC now owns 4,242 shares of the company’s stock valued at $896,000 after acquiring an additional 49 shares in the last quarter. Hillsdale Investment Management Inc. grew its holdings in shares of Cardinal Health by 0.9% during the fourth quarter. Hillsdale Investment Management Inc. now owns 5,760 shares of the company’s stock worth $1,184,000 after buying an additional 50 shares in the last quarter. V Square Quantitative Management LLC raised its holdings in Cardinal Health by 2.6% in the 1st quarter. V Square Quantitative Management LLC now owns 2,002 shares of the company’s stock valued at $423,000 after acquiring an additional 50 shares during the last quarter. Finally, Generali Asset Management SPA SGR increased its stake in Cardinal Health by 11.0% in the fourth quarter. Generali Asset Management SPA SGR now owns 513 shares of the company’s stock valued at $105,000 after purchasing an additional 51 shares during the last quarter. Institutional investors and hedge funds own 87.17% of the company’s stock.

Key Headlines Impacting Cardinal Health

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Profit and guidance beat expectations. Cardinal Health reported fiscal Q4 non-GAAP EPS of $2.91, up from $2.08 a year earlier and $0.49 above consensus. Fiscal 2027 adjusted EPS guidance of $12.40–$12.60 also exceeded the approximately $12.05 analyst estimate, implying 13%–15% growth. Cardinal Health forecasts full-year profit above estimates on specialty drug strength
• Positive Sentiment: Specialty-drug and medtech performance supported earnings. Sustained demand for specialty pharmaceuticals helped drive the outlook, while medical technology profits nearly doubled in the quarter. Cardinal also said it now exclusively serves nearly half of the cell-and-gene therapy market, strengthening its position in a higher-margin growth niche. Cardinal Health nearly doubles medtech profits, fueling Q4 earnings beat
• Positive Sentiment: Large buyback authorization added support. The board approved an additional $5 billion for share repurchases after Cardinal bought back $1.4 billion of stock during fiscal 2026. The company also declared a quarterly dividend of $0.5158 per share, payable October 15. Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results
• Neutral Sentiment: Revenue growth was solid but missed forecasts. Fourth-quarter revenue rose 6% year over year to $63.67 billion, but fell short of the roughly $65.15 billion consensus estimate. Fiscal 2026 operating cash flow reached $5.2 billion and adjusted free cash flow was $5.0 billion. Cardinal Health shares rise as profit beats estimates and outlook tops forecasts
• Negative Sentiment: Some earnings quality and valuation concerns remain. About $0.31 of quarterly adjusted EPS came from a one-time IEEPA tariff refund, while the Global Medical Products and Distribution segment reported declining revenue. With CAH trading near its 52-week high and at an elevated valuation, investors may demand continued execution to justify further gains. Can Cardinal Health’s Strong Earnings Guidance Offset a Mixed Quarter?

About Cardinal Health

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.